The TGA has authorised the use of AstraZeneca’s Evusheld (tixagevimab and cilgavimab). Evusheld is a new COVID-19 protective measure (monoclonal antibodies) designed to prevent COVID-19 infection in vulnerable and immunocompromised individuals who may not mount an adequate immune response to COVID-19 vaccination. There may be a small portion of people with MS who fall in to this category. For more information, click here.